Naurex is a biopharmaceutical company developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system.
Our lead product candidate, rapastinel (GLYX-13), is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder who are unable to achieve an adequate response to their current anti-depressants. Rapastinel has shown rapid, substantial, and sustained antidepressant activity in Phase 2 clinical studies and has been well-tolerated, with none of the psychosis-like side effects that limit other drugs targeting NMDA receptors. Our second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.
In July 2015, Naurex Inc. entered into a definitive agreement to be acquired by Allergan plc. The transaction was successfully closed in August 2015. For more information, please visit www.naurex.com or www.allergan.com.
Company Details
- Employees
- 10
- Address
- Administrator Jobs
- Industry
- Biotechnology
Naurex Inc. Questions
Naurex Inc.'s LinkedIn profile is https://www.linkedin.com/company/naurex-inc-
Naurex Inc. has
10 employees.
View email and phone details for 10
employees at Naurex Inc..
Naurex Inc.'s industry is
Biotechnology
Naurex Inc.'s top competitors are
Cumulus Neuroscience,
Aptinyx Inc.,
Exicure,
Cognito Therapeutics, Inc.,
Mindmed,
Gate Neurosciences,
Syndeio Biosciences,
Naurex,
Naurex,
Monument Biosciences.
Naurex Inc.'s categories are Biotechnology
